Author: Nishtha Mehrotra | EQMint
Hospital stocks came under pressure on October 1 after the Supreme Court raised concerns over steep mark-ups on medicines sold by private hospitals. The court questioned how a medicine costing around ₹2,700 could be sold to patients for nearly ₹27,000, bringing hospital pharmacy pricing and medicine margins into focus.
Stocks including Apollo Hospitals, Max Healthcare and Fortis Healthcare declined during the session as investors assessed the potential impact of tighter regulation on hospital pharmacy revenues. The Supreme Court has discussed a proposed 16% margin on medicines, while the broader debate involves how the Drug Price Control Order (DPCO) 2013 applies to medicines supplied through private hospitals.
The court is scheduled to hear the matter again on October 12, 2026. Any regulatory changes could affect hospital pharmacy income and pricing practices, making the proceedings relevant for investors tracking the healthcare sector.
Disclaimer: This article is for information purposes only and is not investment advice.
For more such information, visit EQMint
Join our WhatsApp channel for timely updates: Whatsapp
